Labiana Health (LAB) Stock Overview
Develops, manufactures, sells, and markets animal and human health medicine products in Spain, North America, rest of European Union, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
LAB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Labiana Health, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.48 |
| 52 Week High | €4.90 |
| 52 Week Low | €2.80 |
| Beta | -0.47 |
| 1 Month Change | 2.28% |
| 3 Month Change | -7.82% |
| 1 Year Change | 49.33% |
| 3 Year Change | 40.00% |
| 5 Year Change | n/a |
| Change since IPO | -2.61% |
Recent News & Updates
Shareholder Returns
| LAB | ES Pharmaceuticals | ES Market | |
|---|---|---|---|
| 7D | -0.4% | -0.3% | 1.2% |
| 1Y | 49.3% | 40.7% | 32.8% |
Return vs Industry: LAB exceeded the Spanish Pharmaceuticals industry which returned 35.9% over the past year.
Return vs Market: LAB exceeded the Spanish Market which returned 33.1% over the past year.
Price Volatility
| LAB volatility | |
|---|---|
| LAB Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 2.9% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in ES Market | 6.4% |
| 10% least volatile stocks in ES Market | 0.7% |
Stable Share Price: LAB's share price has been volatile over the past 3 months compared to the Spanish market.
Volatility Over Time: LAB's weekly volatility (4%) has been stable over the past year, but is still higher than 75% of Spanish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1958 | 394 | Manuel Ortega | www.labiana.com |
Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, North America, rest of European Union, and internationally. The company offers anesthetics-sedative, anti-infective, anti-inflammatory, antiparasitic, hormonal, and nutritional products; metabolism regulators; and vitamin products. It also provides sterile, lyophilized dosage forms, bacterial vaccines and biological formats; and Fosfomycin trometamol under the Fosfomicina Labiana brand name.
Labiana Health, S.A. Fundamentals Summary
| LAB fundamental statistics | |
|---|---|
| Market cap | €31.34m |
| Earnings (TTM) | €904.36k |
| Revenue (TTM) | €71.67m |
Is LAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LAB income statement (TTM) | |
|---|---|
| Revenue | €71.67m |
| Cost of Revenue | €31.00m |
| Gross Profit | €40.67m |
| Other Expenses | €39.77m |
| Earnings | €904.36k |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.13 |
| Gross Margin | 56.74% |
| Net Profit Margin | 1.26% |
| Debt/Equity Ratio | 980.9% |
How did LAB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/25 15:12 |
| End of Day Share Price | 2026/02/25 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Labiana Health, S.A. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Iñigo Recio Pascual | GVC Gaesco Valores |
| Alfredo Echevarria Otegui | Lighthouse-IEAF Servicios de Analisis |
| Luis Esteban Arribas | Lighthouse-IEAF Servicios de Analisis |